RxDoctor Payments Data

Jessica Rivera

Family · Clemson, SCNPI 1437598588

Payments from drug & device makers

$6,432in general payments, 2019–2025

Across 388 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$931
  • Teva Pharmaceuticals USA, Inc.$621
  • Pfizer$564
  • Novo Nordisk$364
  • GSK$223
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,432 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$92,869
Medicare patients
150
Services billed
2,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide86$124,661
OzempicSemaglutide47$55,356
EliquisApixaban57$46,742
JardianceEmpagliflozin38$41,742
LinzessLinaclotide17$22,588
TrulicityDulaglutide15$22,426
XareltoRivaroxaban17$13,296
Ezetimibe53$2,825
Insulin Lispro Kwikpen U-100Insulin Lispro11$2,696
Rosuvastatin Calcium113$2,619
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,421
Duloxetine Hcl43$2,070
Atorvastatin Calcium215$1,870
Potassium Citrate ErPotassium Citrate12$1,818
Levothyroxine Sodium133$1,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$931$147,087101 claims
Novo NordiskOzempic$364$55,35647 claims
PfizerEliquis$564$46,74257 claims
Boehringer IngelheimJardiance$40$41,74238 claims
AbbVieLinzess, Synthroid$1,542$23,11242 claims
Johnson & JohnsonXarelto$24$13,29617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →